Alembic Ltd has floated a new division called ''SynX'' to cater to patients suffering from a condition called Syndrome X, the company informed BSE today.
Syndrome X is a term indicating the association of glucose intolerance, dyslipidemia, hypertension and insulin resistance. These metabolic abornormalities are often associated with insulin resistance.
SynX would have a fortfolio of 8-10 products to begin with.
Alembic is also planning to dedicate a 100 member team for the division. The Rs 5000 million Company expects the division to report a turnover of around Rs 250 million by March 2004. Products that have been brought under this division include nateglinide (Natelide), pioglitazone (Piolem), gliclazide (GLZ, GLZ Plus), glipiside (Glipy), metformin (Forminal, Forminal SR), alprazolam (Zocam), vitamins and minerals (Zivinal CD). The new SynX Division is a part of larger restructuring exercise that has been kicked off within the Company to coincide with the "World Heart Day."
The Company also intends to introduce anti-hypertensives like ramipril and a combination of amlodipine and atenolol as well as lipid regulators like fenofibrate under the new division.